Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Achillion reports positive interim data re ACH-4471

Achillion Pharmaceuticals has reported positive interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small...

| By Kelley Gipson

NextCure reports IPO pricing

NextCure announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share....

| By Kelley Gipson

Trevi Therapeutics raises $55M in IPO

Trevi Therapeutics has gone public, selling 5.5 million shares at $10 a share and raising $55 million. The company, which is developing a drug for...

| By Kelley Gipson

SpringWorks initiates Phase 1b trial of MEK inhibitor

SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor,...

| By Kelley Gipson

Yale-New Haven plans neuroscience center

Yale-New Haven Hospital has unveiled plans to build up its St. Raphael campus with a 505,000-square foot, $838 million neuroscience center for research and treatment...

| By Bill Kelly

BioCT welcomes new member KPMG

KPMG LLP provides tax, audit and advisory services (including strategy, risk, regulatory and M&A) to over 500 life sciences clients in the northeast region. The...

| By Bill Kelly

JAX studies structural variants in human genome

A paper published in Nature Communications delves deeper into individual genomic differences than ever before. The work involved a large international team of researchers from the...